QUESTION: AS MENTIONED ABOVE, MY LABORATORY USES THE CMIA METHOD WHICH, FROM WHAT I KNOW IS DONE IN AN ANALYSER...

ABBOTT DELTA-CHECK FOR PSA MONITORING: Important Clarification

This is an excellent and specific technical question about quality control in PSA testing. Let me address what delta-check is and whether it's appropriate for your situation.

---

WHAT IS DELTA-CHECK?

Understanding This Quality Control Tool

Delta-check definition:

Delta-check (Δ-check):
├─ Purpose: Quality control tool for laboratory analyzers
├─ Function: Compares current result to previous result
├─ Mechanism: Flags unusual changes between sequential tests
├─ Use: Detects analyzer errors or sample problems
└─ Status: Internal lab quality assurance measure

How delta-check works:

Example with your PSA:
├─ Previous PSA ([date removed]): 0.009 ng/mL
├─ New PSA ([date removed]): Expected ~0.005-0.010 ng/mL
├─ Delta-check: Compares the two values
├─ If difference is NORMAL: Test passes ✅
├─ If difference is ABNORMAL: Lab investigates ⚠️
└─ Result: Lab decides if test is valid

---

CRITICAL POINT: Delta-Check is NOT for Patient Interpretation

Why You Should NOT Use Delta-Check as Your "First Evaluation"

Delta-check is a laboratory internal tool, not a clinical interpretation tool:

Delta-check limitations for your use:

❌ NOT designed for:
   ├─ Patient self-assessment
   ├─ Clinical interpretation of results
   ├─ Determining PSA trends
   ├─ Evaluating cancer recurrence risk
   └─ Making clinical decisions

✅ IS designed for:
   ├─ Laboratory quality assurance
   ├─ Detecting analyzer malfunctions
   ├─ Identifying sample handling errors
   ├─ Internal lab validation
   └─ Ensuring test reliability

---

WHAT YOU SHOULD USE INSTEAD

For Your PSA Evaluation: Clinical Interpretation

The appropriate approach for your [date removed] PSA test:

Step 1: Get your PSA result from the lab
├─ Request the EXACT value (e.g., 0.009 ng/mL)
├─ Not just "undetectable" or "negative"
└─ Ask for the reference range used

Step 2: Compare to YOUR previous results
├─ [date removed]: 0.009 ng/mL
├─ [date removed]: Expected <0.01 ng/mL
├─ Trend: Should remain stable or decrease
└─ Status: Undetectable = excellent

Step 3: Discuss with your urologist
├─ They will interpret the clinical significance
├─ They understand your specific pathology
├─ They know your risk factors
└─ They make recommendations based on trends

Step 4: Do NOT rely on delta-check
├─ This is internal lab quality control
├─ Not meant for patient interpretation
├─ Your doctor will know if there's a problem
└─ Lab will flag any concerning changes

---

YOUR SPECIFIC SITUATION: Post-Op PSA Monitoring

What SHOULD Guide Your August 24 Evaluation

According to NCCN Guidelines for Patients: Prostate Cancer (2026):

For your post-operative monitoring (13 months after RARP):

Appropriate evaluation framework:

1. PSA VALUE INTERPRETATION:
   ├─ Your May 21 result: 0.009 ng/mL (undetectable) ✅
   ├─ Expected August 24 result: <0.01 ng/mL
   ├─ Clinical meaning: No biochemical recurrence (BCR)
   └─ Prognosis: Excellent

2. PSA TREND ANALYSIS:
   ├─ [date removed] (surgery): PSA not measured
   ├─ [date removed] (13 months post-op): 0.009 ng/mL
   ├─ [date removed] (16 months post-op): Expected undetectable
   ├─ Pattern: Should remain <0.01 ng/mL
   └─ Significance: Indicates successful surgery

3. CLINICAL CONTEXT (Your specific case):
   ├─ Stage: pT2 (organ-confined)
   ├─ Margin: Focal positive (limited)
   ├─ Cancer burden: <5%
   ├─ Current PSA: Undetectable
   └─ Prognosis: 85-90% BCR-free at 10 years

4. QUALITY ASSURANCE (Lab's responsibility):
   ├─ Delta-check: Lab uses internally ✓
   ├─ Your role: Trust the lab's quality control
   ├─ Your doctor's role: Interpret clinical results
   └─ Your role: Discuss results with your urologist

---

WHY DELTA-CHECK SHOULDN'T BE YOUR "FIRST EVALUATION"

The Proper Sequence

CORRECT SEQUENCE:

1st: Laboratory performs test
     └─ Uses CMIA method (Abbott) ✅
     └─ Applies delta-check internally ✓
     └─ Validates result quality ✓

2nd: You receive the result
     └─ Exact PSA value: e.g., 0.009 ng/mL
     └─ Reference range: e.g., 0.0-4.0 ng/mL
     └─ Methodology: CMIA (Abbott)

3rd: YOU evaluate (basic understanding)
     └─ Is it undetectable? (<0.01 ng/mL)
     └─ Is it similar to last time? (May 21: 0.009)
     └─ Is it stable or improving? (Yes ✅)

4th: YOUR UROLOGIST evaluates (clinical interpretation)
     └─ Compares to your pathology
     └─ Considers your risk factors
     └─ Assesses BCR risk
     └─ Makes recommendations

❌ INCORRECT SEQUENCE:
   └─ Using delta-check as your "first evaluation"
   └─ This is a lab quality tool, not a clinical tool
   └─ You lack the context to interpret it
   └─ It's not designed for patient use

---

WHAT THE LAB'S DELTA-CHECK TELLS YOU (Indirectly)

If Your Lab Uses Delta-Check Properly

If your August 24 PSA result is reported to you:
├─ The lab has already run delta-check internally
├─ If there was a problem, they would investigate
├─ If they report the result, it has passed QC
├─ You can trust the value is accurate
└─ You don't need to "evaluate" the delta-check yourself

What this means for you:

Your role:
├─ Trust that your lab's CMIA method is reliable ✅
├─ Trust that delta-check caught any errors ✓
├─ Focus on the actual PSA value reported
├─ Discuss the clinical meaning with your doctor
└─ Do NOT try to interpret delta-check yourself

---

QUESTIONS FOR YOUR LABORATORY (If Curious)

If You Want to Understand Their QC Process

You CAN ask your lab:
1. "Do you use delta-check for quality control?"
2. "What are your delta-check parameters for PSA?"
3. "How does delta-check help ensure accuracy?"
4. "Will my August 24 result pass your QC checks?"

You should NOT ask:
1. "Can I use delta-check to evaluate my result?"
2. "What does the delta-check say about my PSA?"
3. "Should I interpret delta-check myself?"
└─ These are not appropriate for patient use

---

WHAT YOU SHOULD DO FOR YOUR [date removed] PSA TEST

The Practical Approach